Headache Clinical Trials | NeuroTrials.ai

Does early initiation of erenumab in patients with episodic migraine who failed 1 or 2 previous preventive treatments provide improved long-term efficacy, tolerability, adherence, and patient satisfaction compared with nonspecific oral migraine preventive medication?

APPRAISE

12-Month Prospective, Interventional, Global, Multicenter, Active-Controlled, Randomized Clinical Trial Comparing Sustained Benefit of 2 Treatment Paradigms (Erenumab qm vs Oral Prophylactics) in Adult Episodic Migraine Patients

JAMA Neurology · 2024

Bottom Line: Earlier use of erenumab in patients with episodic migraine who failed 1 or 2 previous preventive treatments provided significantly greater and sustained efficacy, safety, tolerability, and adherence compared with continuous oral preventive medications over 12 months

PATHOPHYSIOLOGY / BIOMARKERS 1

IIH Provoke

2026

In a small (n=16) double-blind, placebo-controlled, two-way crossover provocation study, IV CGRP triggered typical IIH headache in 44% of women and was accompanied by elevations in 8 pro-nociceptive a...

J Headache Pain

TRIGEMINAL NEURALGIA 1

Is IV fosphenytoin superior to placebo in reducing pain intensity at 120 minutes in patients with acute trigeminal neuralgia exacerbations?

IV Fosphenytoin for Trigeminal Neuralgia

2026

Neurology

MIGRAINE 5

Is vaporized cannabis effective for the acute treatment of migraine attacks?

Cannabis for Acute Migraine

2026

Headache: The Journal of Head and Face Pain

Does a single intravenous infusion of Lu AG09222, an anti-PACAP monoclonal antibody, reduce migraine days in patients with prior preventive treatment failures?

HOPE

2024

New England Journal of Medicine

Is vaporized cannabis (THC-dominant, CBD-dominant, or THC+CBD) superior to placebo for the acute treatment of migraine attacks?

CANNABIS MIGRAINE

2024

medRxiv (preprint)

Is CGRP inhibitor use associated with an increased risk of cardiovascular events in patients with migraine?

CGRP-CV

2026

Neurology

Can a CGRP antibody actually prevent migraines in children and teens?

SPACE - Fremanezumab Pediatric

2026

View Details →

CHRONIC MIGRAINE 3

Which treatment strategy—withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinations—is most effective at reducing monthly headache days in patients with medication-overuse headache?

MOH NMA Liu 2025

2025

The Journal of Headache and Pain

Does adding a 28-day prednisone taper to galcanezumab improve outcomes in medication overuse headache compared with either treatment alone?

Steroids + Galcanezumab for MOH

2025

Revue Neurologique

Is atogepant effective for preventive treatment of chronic migraine in patients with and without acute medication overuse?

PROGRESS

2024

Neurology

CLUSTER HEADACHE 2

Do anti-CGRP monoclonal antibodies effectively prevent attacks in episodic and chronic cluster headache?

KOLAKOWSKI ET AL 2026 EFFICACY

2026

Cephalalgia

Can a CGRP antibody prevent episodic cluster headache attacks?

GALiC

2019

View Details →

CLUSTER HEADACHE (CGRP) 1

Is eptinezumab 400 mg IV every 12 weeks safe, tolerable, and effective for long-term prevention of chronic cluster headache?

CHRONICLE

2025

Lancet Neurology

MIGRAINE PROPHYLAXIS 2

Does fremanezumab reduce monthly migraine days and depressive symptoms in patients with migraine and comorbid DSM-5 major depressive disorder?

UNITE

2025

JAMA Neurology

Is amitriptyline an effective migraine prophylactic, and is the benefit independent of its antidepressant action?

Amitriptyline Couch

1976

Neurology

MIGRAINE 1

Does eptinezumab combined with brief patient education reduce migraine burden more than patient education alone in adults with chronic migraine and medication-overuse headache?

RESOLUTION

2026

Neurology